NCT02143804 2026-04-02
exBOND
CG Oncology, Inc.
Phase 2 Withdrawn
Clinical Trials
20 trialsNCT06763965 2026-03-23
Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Phase 1/2 Enrolling by invitation
NCT04695327 2026-03-06
TUNIMO
TILT Biotherapeutics Ltd.
Phase 1 Completed
NCT02705196 2026-02-24
LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
Lokon Pharma AB
Phase 1/2 Completed
NCT06215846 2025-11-26
A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Phase 1 Enrolling by invitation
NCT05271318 2025-11-03
PROTA
TILT Biotherapeutics Ltd.
Phase 1/2 Recruiting
NCT03754933 2025-03-27
Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer
GeoVax, Inc.
Phase 1/2 Completed
NCT04673942 2024-10-26
BETA-PRIME
EpicentRx, Inc.
Phase 2 Recruiting
NCT05305040 2024-05-16
Prevent
AlloVir
Phase 2/3 Terminated
NCT04693637 2024-05-09
Prevent
AlloVir
Phase 2/3 Completed
NCT04097002 2023-10-31
First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients.
Orca Therapeutics B.V.
Phase 1/2 Unknown
NCT02108522 2021-07-20
CHARMS
AlloVir
Phase NA Completed
NCT01438112 2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3 Terminated
NCT00031083 2020-11-17
Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas
Biogen
Phase 1 Completed
NCT01570283 2019-05-30
ARMS
AlloVir
Phase 1/2 Completed
NCT02654938 2017-09-20
Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer
Panacela Labs LLC
Phase 1 Completed
NCT02844699 2017-09-20
A Multicenter Randomized Double-blind Placebo-controlled Pilot Study of Safety, Pharmacodynamics and Efficacy of Different Treatments of Immunotherapeutic Drug Mobilan (M-VM3) in Patients With Diagnosed Prostate Cancer
Panacela Labs LLC
Phase 1/2 Unknown
NCT00625430 2011-07-11
FP253-GDEPT
Biotech Equity Partners Pty Ltd
Phase 1 Unknown
NCT00109655 2008-10-03
Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure
Cell Genesys
Phase 1 Unknown
NCT00116363 2008-04-01
Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma
Introgen Therapeutics
Phase 2 Unknown